ArticleClinical proteomics2013
Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.
Article in Clinical proteomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Ovarian Cyst Fluid as a Resource for Diagnostic and Prognostic Biomarker Discovery in Ovarian Lesions.Cancers · 2026Review
- Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective.Molecular & cellular proteomics : MCP · 2023Review
- Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.International journal of cancer · 2022Article
- Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer.Cancers · 2021Article
- Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.Proteomes · 2021Review
- Ultrasonography in the Diagnosis of Adnexal Lesions: The Role of Texture Analysis.Diagnostics (Basel, Switzerland) · 2021Article
- Radiomic Analysis of MRI Images is Instrumental to the Stratification of Ovarian Cysts.Journal of personalized medicine · 2020Article
- Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.Cancers · 2020Review
- Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers.Journal of clinical medicine · 2020Article
- Proteome profiling of low grade serous ovarian cancer.Journal of ovarian research · 2019Article
- The Extracellular Matrix Protein ABI3BP in Cardiovascular Health and Disease.Frontiers in cardiovascular medicine · 2019Review
- Proteomic Response to Rising Temperature in the Marine CyanobacteriumFrontiers in microbiology · 2019Article
- Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.Journal of ovarian research · 2018Review
- Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery.International journal of molecular sciences · 2018Article
- Comparison of iTRAQ and SWATH in a clinical study with multiple time points.Clinical proteomics · 2018Article
- Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins.Cancer genomics & proteomics · 2017Article
- Article
- Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.Oncotarget · 2015Article
- Proteomics of ovarian cancer: functional insights and clinical applications.Cancer metastasis reviews · 2015Review
- Early inflammatory response in epithelial ovarian tumor cyst fluids.Cancer medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpithelial-derived ovarian adenocarcinoma (EOC) is the most deadly gynecologic tumor, and the principle cause of the poor survival rate is diagnosis at a late stage. Screening and diagnostic biomarkers with acceptable specificity and sensitivity are lacking. Ovarian cyst fluid should harbor early ovarian cancer biomarkers because of its closeness to the tumor. We investigated ovarian cyst fluid as a source for discovering biomarkers for use in the diagnosis of EOC.
resultsUsing quantitative mass spectrometry, iTRAQ MS, we identified 837 proteins in cyst fluid from benign, EOC stage I, and EOC stage III. Only patients of serous histology were included in the study. Comparing the benign (n = 5) with the malignant (n = 10) group, 87 of the proteins were significantly (p < 0.05) differentially expressed. Two proteins, serum amyloid A-4 (SAA4) and astacin-like metalloendopeptidase (ASTL), were selected for verification of the iTRAQ method and external validation with immunoblot in a larger cohort with mixed histology, in plasma (n = 68), and cyst fluid (n = 68). The protein selections were based on either high significance and high fold change or abundant appearance and several peptide recognitions in the sample sets (p = 0.04, FC = 1.95) and (p < 0.001, FC = 8.48) for SAA4 and ASTL respectively. Both were found to be significantly expressed (p < 0.05), but the methods did not correlate concerning ASTL.
conclusionsFluid from ovarian cysts connected directly to the primary tumor harbor many possible new tumor-specific biomarkers. We have identified 87 differentially expressed proteins and validated two candidates to verify the iTRAQ method. However several of the proteins are of interest for validation in a larger setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.